iRECIST Guideline Unveiled for Immunotherapies
- PMID: 28302600
- DOI: 10.1158/2159-8290.CD-NB2017-037
iRECIST Guideline Unveiled for Immunotherapies
Abstract
The new iRECIST guideline-developed in consultation with academics, drug companies, and regulatory authorities-provides a standardized approach to assessing whether patients' disease improves, stays the same, or worsens in trials of immunotherapeutics, agents that can trigger different response patterns from other kinds of drugs.
©2017 American Association for Cancer Research.
Comment on
-
iRECIST: guidelines for response criteria for use in trials testing immunotherapeutics.Lancet Oncol. 2017 Mar;18(3):e143-e152. doi: 10.1016/S1470-2045(17)30074-8. Epub 2017 Mar 2. Lancet Oncol. 2017. PMID: 28271869 Free PMC article. Review.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Other Literature Sources